Literature DB >> 7537249

Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.

T Belay1, R Cherniak.   

Abstract

The competitive binding specificities of glucuronoxylomannan (GXM) and its derivatives to factor sera of Cryptococcus neoformans were studied by enzyme-linked immunosorbent assay. An effort was made to determine the epitope specificity of each factor serum. Despite the presence of antigenic factor 1 on all serotypes of C. neoformans, variations in inhibition ability were observed with different GXMs. The panspecific component of factor serum 1 (antibody 1) appeared to be due to the presence of more than one antibody component. The activity was dependent on the 6-O-acetyl substituent. GXMs of serotypes A and D inhibited factor serum 2 equally well, indicating a low titer for the antibody 7 component. Serotype B GXM was a poor inhibitor, and serotype C GXM did not inhibit factor serum 2. The activity of factor serum 2 was 6-O-acetyl dependent. GXMs from typical serotype A and serotype D isolates were excellent inhibitors of factor serum 3. GXMs from serotype B were poorly inhibitory and serotype C did not inhibit factor serum 3. The activity of factor serum 3 was 6-O-acetyl dependent. The activity of factor serum 4 was due predominantly to antibody component 6. The activity of factor 4 was directed mainly against serotype C, and it was independent of 6-O-acetyl substitution Factor serum 5 was specific for serotype B GXMs. The inhibitory effect was independent of 6-O-acetyl substitution, but the effect was diminished by reduction of the glucuronic acid. The GXMs with a typical serotype C structure inhibited antibody 6. O deacetylation of the GXMs did not affect their inhibitory activity. However, reduction of glucuronic acid reduced factor serum 6 binding. Factor serum 8 was specific to serotype D; native GXMs of serotype A were slightly inhibitory. O deacetylation of the serotype D GXMs abrogated the inhibitory effect. O deacetylation alone abrogates the activity of antibody components 1, 2, 3, and 8. Reduction of glucuronic acid reduces the inhibitory activity of the GXM to antibody components 4, 5, and 6. Partial GXM structures and methyl glycosides did not effectively inhibit the activity of any of the factor sera.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537249      PMCID: PMC173229          DOI: 10.1128/iai.63.5.1810-1819.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Glucuronoxylomannan of Cryptococcus neoformans serotype C: structural analysis by gas-liquid chromatography-mass spectrometry and 13C-nuclear magnetic resonance spectroscopy.

Authors:  R Cherniak; L C Morris; S A Meyer
Journal:  Carbohydr Res       Date:  1992-03-02       Impact factor: 2.104

2.  The antigenic composition of Cryptococcus neoformans. I. A serologic classification by means of the capsular and agglutination reactions.

Authors:  E E EVANS
Journal:  J Immunol       Date:  1950-05       Impact factor: 5.422

3.  Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.

Authors:  A Casadevall; J Mukherjee; S J Devi; R Schneerson; J B Robbins; M D Scharff
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

4.  Glucuronoxylomannan of Cryptococcus neoformans obtained from patients with AIDS.

Authors:  R Cherniak; L C Morris; S A Meyer; T B Mitchell
Journal:  Carbohydr Res       Date:  1993-11-03       Impact factor: 2.104

Review 5.  Therapy for cryptococcal meningitis in patients with AIDS.

Authors:  W G Powderly
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

6.  Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T Shinoda
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

Review 7.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans.

Authors:  M Pettoello-Mantovani; A Casadevall; T R Kollmann; A Rubinstein; H Goldstein
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

9.  Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans.

Authors:  R Cherniak; L C Morris; B C Anderson; S A Meyer
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  Structural variability in the glucuronoxylomannan of Cryptococcus neoformans serotype A isolates determined by 13C NMR spectroscopy.

Authors:  S H Turner; R Cherniak; E Reiss; K J Kwon-Chung
Journal:  Carbohydr Res       Date:  1992-09-02       Impact factor: 2.104

View more
  14 in total

1.  Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Mol Microbiol       Date:  2009-09-02       Impact factor: 3.501

2.  Extracellular proteins of Cryptococcus neoformans and host antibody response.

Authors:  L C Chen; L A Pirofski; A Casadevall
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Proteins in the cell wall and membrane of Cryptococcus neoformans stimulate lymphocytes from both adults and fetal cord blood to proliferate.

Authors:  C H Mody; K L Sims; C J Wood; R M Syme; J C Spurrell; M M Sexton
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

4.  In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.

Authors:  W Cleare; R Cherniak; A Casadevall
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

5.  Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.

Authors:  Thomas R Kozel; Stuart M Levitz; Françoise Dromer; Marcellene A Gates; Peter Thorkildson; Guilhem Janbon
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

6.  Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.

Authors:  Ann Percival; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

7.  Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T R Kozel; A Casadevall
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

8.  Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene.

Authors:  Y C Chang; R Cherniak; T R Kozel; D L Granger; L C Morris; L C Weinhold; K J Kwon-Chung
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

9.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

10.  Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.

Authors:  R Cherniak; L C Morris; T Belay; E D Spitzer; A Casadevall
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.